(CIDRAP News) A pharmaceutical company is reporting good results in the first clinical trial of an H5N1 avian influenza vaccine that uses a whole, killed H5N1 virus grown in cell culturea combination of techniques that entails some risk but may boost immune response and shorten production time.
(CIDRAP News) Disease experts and preparedness advocates reacted negatively today to comments by the head of the World Organization for Animal Health (OIE) suggesting that the risk of an influenza pandemic posed by the H5N1 avian flu virus is minimal.
(CIDRAP News) This in-depth article investigates the prospects for development of vaccines to head off the threat of an influenza pandemic posed by the H5N1 avian influenza virus. Its seven parts put advances in vaccine technology in perspective by illuminating the formidable barriers to producing an effective and widely usable vaccine in a short time frame.
(CIDRAP News) An international research team led by the University of Wisconsin at Madison (UW-Madison) has identified a key mutation that would arm the H5N1 avian influenza virus with one of the tools it needs to more easily infect and spread among humans.
(CIDRAP News) Antibodies gleaned from four Vietnamese patients who survived H5N1 avian influenza were used successfully to prevent and treat H5N1 infection in mice, suggesting that the same approach might be useful in humans, according to a recent report by an international team of researchers.
(CIDRAP News) A virus recovered from victims of the 1918 influenza pandemic kills by replicating so rapidly that it revs the immune system into overdrive, turning the body against itself, a team of scientists report in today's issue of the journal Nature.
(CIDRAP News) A group of influenza experts convened by the World Health Organization cautioned today that governments shouldn't stockpile "pre-pandemic" H5N1 influenza vaccines now, because too little is known about the requirements for an effective vaccine.
(CIDRAP News) – Low doses of a cell-based avian flu vaccine triggered a good immune response to the H5N1 avian influenza virus, according to preliminary results of a clinical trial by Baxter International of Deerfield, Ill., maker of the vaccine.